Vera Therapeutics develops treatments for serious immunological diseases, with company updates centered on atacicept, a self-administered fusion protein designed to block BAFF and APRIL activity involved in autoantibody production. News commonly covers the atacicept program in IgA nephropathy, related autoimmune kidney disease research, clinical data from the ORIGIN and PIONEER programs, FDA regulatory communications, and preparations tied to potential commercialization.
Other recurring developments include quarterly financial results, balance sheet and financing commentary, participation in health care conferences, board and executive appointments, and equity-based inducement awards under Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics (VERA) announced that TRUTAKNA achieved statistical significance across all prespecified endpoints in the ORIGIN 3 final efficacy analysis. The trial studied adults with primary IgA nephropathy at risk for disease progression. Results included changes in estimated kidney filtration rate, its annualized slope, and reduced risk of composite kidney disease progression events. The primary endpoint of reduced urine protein at 36 weeks was also met.
Adverse events occurred in 75% of TRUTAKNA patients versus 78% on placebo; serious adverse events occurred in 7% versus 15%. Vera plans a supplemental biologics license application in Q4 2026, with potential full FDA approval in 2027. TRUTAKNA currently has accelerated approval to reduce urine protein; long-term slowing of kidney function decline has not been established. Results were presented at ASN Kidney Week 2026 and published in The New England Journal of Medicine.
Vera Therapeutics (VERA) will host an investor webcast on October 22, 2026, to discuss final efficacy results from its ORIGIN 3 trial. The webcast begins at 4:30 p.m. ET and covers TRUTAKNA in IgA nephropathy, an immune-mediated kidney disease. The results will be featured in a late-breaking oral presentation during the opening plenary session of ASN Kidney Week 2026. Jonathan Barratt of the University of Leicester will join management, with a live question-and-answer session following the presentation.
A separate webcast on November 5, 2026, at 4:30 p.m. ET will cover third-quarter 2026 financial results and business updates. Replays of both webcasts will be available for 90 days through the News & Events section of Vera’s investor website.
Vera Therapeutics (VERA) granted stock options and restricted stock units to five new employees on September 29, 2026.
The inducement awards cover options to purchase 16,700 Class A shares and restricted stock units (RSUs) underlying 8,350 Class A shares. The options have a $32.38 exercise price, equal to the closing trading price on the grant date. Options vest over four years: 25% on the first anniversary of the applicable vesting commencement date, then monthly over 36 months. RSUs vest over four years, with 25% on each anniversary of November 20. Both require continued service through the applicable vesting dates. The Compensation Committee approved the grants under the Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics (VERA) will present the ORIGIN 3 final efficacy analysis of TRUTAKNA at ASN Kidney Week on October 22, 2026. The analysis in IgA nephropathy (IgAN) will feature in the opening plenary session and a late-breaking research poster.
The conference runs October 22–25 in Denver, with five Vera-sponsored abstracts scheduled. An October 24 oral presentation will cover interim results from the adult IgAN and primary membranous nephropathy cohorts of PIONEER, a Phase 2 trial of atacicept. Other posters address pediatric IgAN evaluation, real-world disease control and a clinical implementation network.
Vera Therapeutics (VERA) reported final efficacy results from the Phase 3 ORIGIN 3 trial showing that TRUTAKNA (atacicept-vymj) stabilized kidney function and reduced kidney disease progression over two years in adults with primary IgA nephropathy at risk for progression.
Through 52 weeks, mean eGFR change was -0.1 mL/min/1.73m2 with TRUTAKNA versus -5.7 with placebo, a placebo-adjusted difference of 5.6 (p<0.0001). The annualized eGFR slope through 104 weeks was -0.6 mL/min/1.73m2/year with TRUTAKNA versus -5.6 with placebo, a 5.0 difference (p<0.0001). Composite kidney disease progression events through 104 weeks were 11 on TRUTAKNA versus 38 on placebo, a hazard ratio of 0.24 with a 76% risk reduction (p<0.0001), and there were 0 versus 8 events of dialysis ≥30 days, transplant, or death.
TRUTAKNA met all prespecified endpoints, including statistically significant reductions in proteinuria, Gd-IgA1, and hematuria, and had an overall safety profile generally comparable to placebo. Vera reports strong commercial launch momentum, with over 350 patient start forms in the first ten weeks after accelerated approval, and plans to submit a supplemental BLA for full FDA approval in the fourth quarter of 2026.
Vera Therapeutics (VERA) granted inducement equity awards on September 1, 2026 to six new employees under its 2024 Inducement Plan, in line with Nasdaq Listing Rule 5635(c)(4).
The grants include non-qualified stock options to purchase 61,500 Class A shares at an exercise price of $34.23 per share and RSUs covering 30,750 Class A shares. Options vest over four years, with 25% after one year and the remainder monthly over 36 months. RSUs vest 25% annually over four years from either August 20 or November 20, 2026, depending on employee start date, subject to continued service.
Vera Therapeutics (Nasdaq: VERA) will participate in two investor conferences in New York. The company will host fireside chats and 1x1 investor meetings at the Cantor Global Healthcare Conference on September 10, 2026, at 8:00am ET, and at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, at 5:35pm ET. Webcasts for both events will be accessible online, with replays available for 90 days via the News & Events section of Vera Therapeutics’ website.
Vera Therapeutics (Nasdaq: VERA) reported Q2 2026 results and a major regulatory milestone: the FDA granted accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk for disease progression, and the U.S. launch is underway.
The approval was based on ORIGIN Phase 3 data showing a 46% proteinuria reduction from baseline and 42% versus placebo at 36 weeks, plus a 68% reduction in Gd-IgA1 and 81% hematuria resolution, with generally tolerable safety. Vera aligned with FDA on an earlier ORIGIN 3 final efficacy analysis, expected in Q3 2026, to support a potential full approval, with an sBLA planned for Q4 2026 and possible full approval in 2027.
For Q2 2026, Vera reported a net loss of $109.5 million ($1.52 per share) versus $76.5 million ($1.20 per share) a year earlier. Cash, cash equivalents and marketable securities totaled $499.2 million at June 30, 2026, with up to $425 million remaining available under its debt facility, subject to conditions.
Vera Therapeutics (Nasdaq: VERA) reported that its Board Compensation Committee granted Nasdaq Listing Rule 5635(c)(4) inducement equity awards under the 2024 Inducement Plan on August 3–4, 2026. The grants include non-qualified stock options for 63,011 shares and RSUs for 44,987 shares to new Chief Regulatory Officer Nancy Bowman, M.D., Ph.D., and options for 5,600 shares plus RSUs for 2,800 shares to two new employees.
Options granted on August 3 have an exercise price of $32.23 per share, and those granted on August 4 have a $29.95 exercise price. Options vest over four years with 25% after one year and the remainder monthly over 36 months. RSUs vest 25% annually on each August 20 over four years, all subject to continued service and award agreements.
Vera Therapeutics (Nasdaq: VERA) reported that on July 6, 2026, its Board Compensation Committee granted inducement equity awards to eight new employees under the 2024 Inducement Plan. The grants include non-qualified stock options for 32,100 Class A shares at an exercise price of $40.13 and RSUs for 16,050 Class A shares, all vesting over four years, in accordance with Nasdaq Listing Rule 5635(c)(4).